ELISA/assay

Rat Osteoprotegerin ELISA Kit

MBS044105

48-Strip-Wells

435 USD

ELISA Kit

Rat Osteoprotegerin ELISA Kit

Osteoprotegerin

osteoprotegerin; Tumor necrosis factor receptor superfamily member 11B; tumor necrosis factor receptor superfamily member 11B; osteoprotegerin; osteoclastogenesis inhibitory factor; tumor necrosis factor receptor superfamily, member 11b; Osteoclastogenesis inhibitory factor; Osteoprotegerin

OPG

TNFRSF11B; TNFRSF11B; OPG; TR1; OCIF; OCIF; OPG

TR11B_HUMAN

Rat

No significant cross-reactivity or interference between Rat OPG and analogues was observed.

Store all reagents at 2-8 degree C

Samples: Serum, Plasma, Tissue Homogenate, Feces and Urine. Assay Type: Sandwich. Detection Range: 0.25 ng/ml - 8 ng/ml. Sensitivity: 0.1 ng/ml.

Intended Uses: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! It is intended to be determinated OPG concentrations in Rat serum, plasma and other body fluids. Using Purified Rat OPG antibody to coat Microelisa Stripplate wells to make solid-phase antibody, then add OPG and OPG antibody which has been labeled with HRP to wells, then the reactants become antibody-antigen-antibody-enzyme complex, after washing completely, add TMB substrate solution, TMB substrate becomes blue color under HRP enzyme-catalyzed, reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. The concentration of OPG in the samples is then determined by comparing the O.D. of the samples to the standard curve. Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean ×100]

Background: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! It is intended to be determinated OPG concentrations in Rat serum, plasma and other body fluids. Using Purified Rat OPG antibody to coat Microelisa Stripplate wells to make solid-phase antibody, then add OPG and OPG antibody which has been labeled with HRP to wells, then the reactants become antibody-antigen-antibody-enzyme complex, after washing completely, add TMB substrate solution, TMB substrate becomes blue color under HRP enzyme-catalyzed, reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. The concentration of OPG in the samples is then determined by comparing the O.D. of the samples to the standard curve.

2072185

AAB53709.1

O00300

46,026 Da

Apoptosis Modulation And Signaling Pathway (198822); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Monoamine Transport Pathway (198851); Osteoblast Signaling Pathway (198842); Osteoclast Signaling Pathway (198769); Osteoclast Differentiation Pathway (193147); Osteoclast Differentiation Pathway (193096); RANKL/RANK Signaling Pathway (672447)

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal. Protein type: Secreted; Inhibitor; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 8q24. Cellular Component: extracellular space; proteinaceous extracellular matrix; extracellular region. Molecular Function: cytokine activity; receptor activity. Biological Process: response to drug; extracellular matrix organization and biogenesis; response to magnesium ion; negative regulation of odontogenesis of dentine-containing teeth; response to estrogen stimulus; apoptosis; response to arsenic; negative regulation of bone resorption; signal transduction; skeletal development; response to nutrient. Disease: Paget Disease, Juvenile

48-Strip-Wells

435 USD

96-Strip-Wells

600